This article was added by the user . TheWorldNews is not responsible for the content of the platform.

AstraZeneca is EU-backed for targeted breast cancer treatment

NEWYou can now listen to Fox News articles!

AstraZeneca announced on Mondaytwo existing therapies to boost its oncology portfolio in the treatment of certain high-risk breast cancer patients in the European Union. Said that was recommended.

Lymphalza, an anticancer drug developed in collaboration with US-based Merck, can be used alone or with endocrine therapy in adults with genetically mutated forms of early-stage breast cancer. Assisted for the combination.

A drug that received similar recommendations in the United States in Marchis an important asset of AstraZeneca. It was recommended for patients with low to normal levels of a protein known as HER2, which is the target of several new therapies.

AstraZeneca buys Alexion for $ 39 billion to expand immunology

The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021.

The AstraZeneca logo was seen outside the North American headquarters in Wilmington, Delaware, USA, March 22, 2021. increase.( REUTERS / Rachel Wisnievsky / File photo)

The Enhertz co-developed with Daiichi Sankyo in Japan isBreast cancer characterized by a high proportion of HER2.

AstraZeneca wins $ 4 billion in COVID-19 vaccine sales

Enhertu is considered a major growth driver for AstraZeneca And some analysts expect a peak in sales of $ 10 billion. Following the success of a recent trial, the drug is expected to be cleared in patients with low HER2 levels this month.